Medindia

X

FDA Approves Optimer's DIFICID™ (fidaxomicin) Tablets for the Treatment of Patients with Clostridium difficile-Associated Diarrhea (CDAD)

Saturday, May 28, 2011 General News J E 4
Advertisement
- In two CDAD clinical trials, DIFICID was non-inferior to vancomycin in clinical response at the end of therapy and superior to vancomycin in sustained clinical response 25 days post-treatment -

Contacts:

Optimer Pharmaceuticals, Inc.

John D. Prunty, Chief Financial Officer & Senior Vice President, Finance

858-909-0736

Canale Communications, Inc.

Jason I. Spark, Senior Vice President

619-849-6005

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Zimmer Holdings to Present at the Goldman Sachs 32...
S
FDA Approves Treatment for Clostridium difficile I...